Summit Therapeutics SMMT
$9.95 −$0.62 (-5.87%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $10.08 +1.31%
Open$10.28
Prev close$10.57
Day range$9.89 – $10.61
Volume7.22M
Market cap$7.96B
P/E (TTM)–
Dividend yield–
SMMT Stock News
Headlines matching Summit Therapeutics or the SMMT ticker, most recent first.
- Jefferies Upgrades Summit Therapeutics(SMMT.US) to Buy Rating, Raises Target Price to $25 Positive
- A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $16 to $43
- Clear Street Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $31
- H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Hold Rating
- Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Maintains Target Price $18
- UBS Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $33
- Citi Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40
- Goldman Sachs Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $41
- Wells Fargo Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $30
- Wolfe Research Initiates Summit Therapeutics(SMMT.US) With Hold Rating
- Bernstein Maintains Summit Therapeutics(SMMT.US) With Sell Rating, Maintains Target Price $9.8
- Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $38
- TD Cowen Maintains Summit Therapeutics(SMMT.US) With Buy Rating
- A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $15 to $40
- A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $16 to $40
No comments yet — be the first to weigh in on SMMT.
Sign in to join the discussion.